Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 43, Issue 11, Pages 2291-2297Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2007.12.021
Keywords
Dendrimer; Pharmacodynamic; Pharmacokinetic; Complex; Conjugate; Drug delivery system
Categories
Funding
- Natural Science Foundation of Anhui Province [070413112]
- Hefei National Laboratory for Physical Sciences at Microscale [C07-06]
Ask authors/readers for more resources
Dendrimers are a new class of artificial macromolecules with several attractive properties that show promises in several biomedical applications. They can be widely used to increase the cellular uptake, bioavailability and therapeutic efficacy, to optimize the biodistribution and intracellular release profile, and to reduce the systemic toxicity, clearance and degradation rate of non-covalently or covalently attached drugs. Recent studies in this aspect clearly point to the potential advantages of dendrimers for the design of new drug delivery systems. Before final applications of dendrimer-based drug delivery systems in humans, we should not only address the benefits of these systems, but also assess the long-term pharmacodynamic (PD) and pharmacokinetic (PK) behaviors and health risk of them. In this mini-review, we will mainly discuss the influence of dendrimers on the PD and PK behaviors of drugs complexed or conjugated to them. (C) 2008 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available